A Controlled Randomized Open-label Multicenter Study Evaluating if Early Conversion to Everolimus (Certican) From Cyclosporine (Neoral) in de Novo Renal Transplant Recipients Can Improve Long-term Renal Function and Slow Down the Progression of Chronic Allograft Nephropathy

Trial Profile

A Controlled Randomized Open-label Multicenter Study Evaluating if Early Conversion to Everolimus (Certican) From Cyclosporine (Neoral) in de Novo Renal Transplant Recipients Can Improve Long-term Renal Function and Slow Down the Progression of Chronic Allograft Nephropathy

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms CENTRAL
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 07 May 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 19 Jul 2012 Primary endpoint 'Glomerular-filtration-rate' has been met.
    • 26 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top